NASDAQ:BLFS - Nasdaq - US09062W2044 - Common Stock - Currency: USD
25.27
+0.67 (+2.72%)
The current stock price of BLFS is 25.27 USD. In the past month the price increased by 12.61%. In the past year, price increased by 40.16%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
TMO | THERMO FISHER SCIENTIFIC INC | 19.34 | 159.89B | ||
DHR | DANAHER CORP | 26.72 | 142.45B | ||
A | AGILENT TECHNOLOGIES INC | 20.46 | 30.97B | ||
IQV | IQVIA HOLDINGS INC | 13.78 | 27.06B | ||
MTD | METTLER-TOLEDO INTERNATIONAL | 27.19 | 22.92B | ||
WAT | WATERS CORP | 29.52 | 20.85B | ||
WST | WEST PHARMACEUTICAL SERVICES | 31.82 | 15.18B | ||
ILMN | ILLUMINA INC | 31.79 | 12.33B | ||
ICLR | ICON PLC | 10.42 | 11.80B | ||
RVTY | REVVITY INC | 19.06 | 11.29B | ||
TEM | TEMPUS AI INC | N/A | 9.87B | ||
QGEN | QIAGEN N.V. | 19.52 | 9.32B |
BioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. The company is headquartered in Bothell, Washington and currently employs 159 full-time employees. The firm facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
BIOLIFE SOLUTIONS INC
Suite 310, 3303 Monte Villa Parkway
Bothell WASHINGTON 98021 US
CEO: Michael Rice
Employees: 159
Phone: 14254011400
The current stock price of BLFS is 25.27 USD. The price increased by 2.72% in the last trading session.
The exchange symbol of BIOLIFE SOLUTIONS INC is BLFS and it is listed on the Nasdaq exchange.
BLFS stock is listed on the Nasdaq exchange.
15 analysts have analysed BLFS and the average price target is 31.96 USD. This implies a price increase of 26.47% is expected in the next year compared to the current price of 25.27. Check the BIOLIFE SOLUTIONS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BIOLIFE SOLUTIONS INC (BLFS) has a market capitalization of 1.20B USD. This makes BLFS a Small Cap stock.
BIOLIFE SOLUTIONS INC (BLFS) currently has 159 employees.
BIOLIFE SOLUTIONS INC (BLFS) has a support level at 24.49 and a resistance level at 27.78. Check the full technical report for a detailed analysis of BLFS support and resistance levels.
The Revenue of BIOLIFE SOLUTIONS INC (BLFS) is expected to decline by -9.4% in the next year. Check the estimates tab for more information on the BLFS EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BLFS does not pay a dividend.
BIOLIFE SOLUTIONS INC (BLFS) will report earnings on 2025-05-08, after the market close.
BIOLIFE SOLUTIONS INC (BLFS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.51).
The outstanding short interest for BIOLIFE SOLUTIONS INC (BLFS) is 8.29% of its float. Check the ownership tab for more information on the BLFS short interest.
ChartMill assigns a technical rating of 7 / 10 to BLFS. When comparing the yearly performance of all stocks, BLFS is one of the better performing stocks in the market, outperforming 88.57% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to BLFS. No worries on liquidiy or solvency for BLFS as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months BLFS reported a non-GAAP Earnings per Share(EPS) of -0.51. The EPS increased by 55.65% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -5.05% | ||
ROE | -5.78% | ||
Debt/Equity | 0.01 |
ChartMill assigns a Buy % Consensus number of 83% to BLFS. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of 73% and a revenue growth -9.4% for BLFS